Vikash Dadlani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11788571/publications.pdf

Version: 2024-02-01

20 papers	1,051 citations	840776 11 h-index	888059 17 g-index
20 all docs	20 docs citations	20 times ranked	944 citing authors

#	Article	IF	Citations
1	Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 1707-1717.	27.0	643
2	Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia. Diabetes Care, 2017, 40, 1719-1726.	8.6	68
3	Adjustment of Open-Loop Settings to Improve Closed-Loop Results in Type 1 Diabetes: A Multicenter Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3878-3886.	3.6	67
4	Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technology and Therapeutics, 2021, 23, 342-349.	4.4	58
5	Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care, 2020, 43, 607-615.	8.6	40
6	Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2020, 43, 1822-1828.	8.6	34
7	Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial. Diabetes Technology and Therapeutics, 2021, 23, 673-683.	4.4	30
8	Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes. Current Diabetes Reports, 2018, 18, 88.	4.2	26
9	Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1954-1962.	3.6	24
10	Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. Diabetes Technology and Therapeutics, 2021, 23, 245-252.	4.4	13
11	Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System. Diabetes Technology and Therapeutics, 2021, 23, 791-798.	4.4	13
12	Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation. Clinical Transplantation, 2019, 33, e13719.	1.6	11
13	Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1208-1216.	2.2	8
14	Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 357-361.	4.4	7
15	High Glucose Variability in Hospitalized Patients with Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2017, 19, 572-579.	4.4	4
16	Assessment of Interday Glucose Variability in Type 2 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 443-445.	4.4	3
17	Continuous Glucose Monitor Use and Accuracy in Hospitalized Patients. Diabetes Technology and Therapeutics, 2016, 18, 449-451.	4.4	2
18	Role of Automation/Technology in Day-to-Day Diabetes Care. Diabetes Technology and Therapeutics, 2016, 18, 273-275.	4.4	0

#	Article	IF	Citations
19	P.157: NK and B Cell Subset Assessment in Type I Diabetes Patients on Waitlist for Pancreas Transplantation. Transplantation, 2021, 105, S65-S65.	1.0	0
20	P.155: Altered T Cell Compartment in Type 1 Diabetes With End Stage Renal Disease. Transplantation, 2021, 105, S63-S64.	1.0	0